Financial Alternatives’s Tandem Diabetes Care TNDM Stock Holding History

Financial Alternatives’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,223	Closed	-$252K	–	78
2023 Q1	$252K	Hold	6,223	–	–	0.24%	65
2022 Q4	$280K	Buy	+6,223	New	+$282K	0.28%	62

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Financial Alternatives's TNDM Position: Q2 2023 in Review

Financial Alternatives sold out of Tandem Diabetes Care (TNDM) in Q2 2023, closing a stake of 6,223 shares — an estimated $252K sold.

Financial Alternatives first reported a position in TNDM in Q4 2022 and held it in 2 quarters. The position peaked at $280K in Q4 2022. 247 funds tracked by Wall St. Rank hold TNDM as of Q2 2023.

Financial Alternatives reported no remaining Tandem Diabetes Care position as of Q2 2023 after selling out during the quarter.
Financial Alternatives sold 6,223 Tandem Diabetes Care shares in Q2 2023, an estimated $252K.
Financial Alternatives first reported a position in Tandem Diabetes Care in Q4 2022 and held it in 2 quarters.
Financial Alternatives's Tandem Diabetes Care position peaked at $280K in Q4 2022.
247 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2023.

Based on Financial Alternatives's 13F filing for Q2 2023, filed 11 Aug 2023.